Insider Selling: Xencor (NASDAQ:XNCR) SVP Sells 1,492 Shares of Stock

Xencor, Inc. (NASDAQ:XNCR) SVP Celia Eckert sold 1,492 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $11.90, for a total value of $17,754.80. Following the completion of the sale, the senior vice president owned 81,929 shares in the company, valued at approximately $974,955.10. The trade was a 1.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Xencor Stock Up 6.0%

XNCR traded up $0.72 during trading on Wednesday, hitting $12.74. The stock had a trading volume of 704,223 shares, compared to its average volume of 590,924. Xencor, Inc. has a twelve month low of $6.92 and a twelve month high of $18.69. The company has a market capitalization of $934.35 million, a PE ratio of -10.27 and a beta of 0.95. The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.25 and a current ratio of 6.25. The stock has a 50 day simple moving average of $12.96 and a two-hundred day simple moving average of $12.91.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.55. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The firm had revenue of $28.24 million during the quarter, compared to analysts’ expectations of $29.97 million. During the same period last year, the business posted ($0.62) earnings per share. The company’s revenue for the quarter was down 46.6% compared to the same quarter last year. On average, research analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current year.

Hedge Funds Weigh In On Xencor

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Amalgamated Bank lifted its holdings in Xencor by 4.8% in the third quarter. Amalgamated Bank now owns 20,846 shares of the biopharmaceutical company’s stock worth $245,000 after purchasing an additional 947 shares during the period. ProShare Advisors LLC grew its holdings in shares of Xencor by 6.5% during the fourth quarter. ProShare Advisors LLC now owns 16,853 shares of the biopharmaceutical company’s stock valued at $258,000 after buying an additional 1,026 shares in the last quarter. Cerity Partners LLC lifted its stake in Xencor by 3.8% in the 4th quarter. Cerity Partners LLC now owns 31,302 shares of the biopharmaceutical company’s stock worth $479,000 after acquiring an additional 1,143 shares in the last quarter. HighVista Strategies LLC boosted its holdings in shares of Xencor by 4.3% during the second quarter. HighVista Strategies LLC now owns 33,304 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 1,362 shares during the period. Finally, GAMMA Investing LLC grew its holdings in shares of Xencor by 77.1% during the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 1,449 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Wedbush reissued an “outperform” rating and set a $26.00 target price on shares of Xencor in a report on Thursday, November 6th. Barclays lifted their price objective on Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. JPMorgan Chase & Co. reduced their target price on shares of Xencor from $20.00 to $18.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a research report on Monday, December 29th. Finally, Wall Street Zen cut Xencor from a “hold” rating to a “sell” rating in a research note on Saturday. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.